Floatz logo

Imiquimod

Medulloblastoma

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Medulloblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Pfizer
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 2B
ETOPOSIDE
Theodore S. Johnson
Phase 2B
Indoximod
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

Imiquimod is also rated in:

lentigo maligna melanomaDormant
BBB
Indicative ·
77 / 100
View asset →
squamous cell intraepithelial neoplasiaDormant
B
Indicative ·
63 / 100
View asset →
human papilloma virus infectionDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →